Xeomin (incobotulinumtoxinA) is a new formulation of botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. Under natural conditions, Clostridium botulinum produces its toxin in association with additional complexing proteins. Historically, manufacturers have utilized this naturally occurring protein complex to produce therapeutic botulinum toxin products. The manufacturer of Xeomin uses a proprietary process that isolates the therapeutic component of botulinum toxin and eliminates the ancillary complexing proteins. In that regard, Xeomin has been formulated to have high biologic activity with a low protein load. Lower protein loads have been suggested to decrease the likelihood of developing neutralizing antibodies over time.
http://www.lexi.com/individuals/pharmacists/newsletters.jsp?id=august_10&utm_source=bdnewsletter&utm_medium=email&utm_campaign=august&contactID=14694955&gwkey=KYQPILTL7B
1 comment:
hi
Post a Comment